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1. Introduction 
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare and heterogeneous 
neoplasms with overall increasing incidence, but not an associated increase in survival rate 
over the past few decades. Tumors originate from at least 16 different cells of diffuse 
endocrine system (DES), scattered through mucosa of gastrointestinal tract. They are mainly 
sporadic, but sometimes exhibit familial inheritance. Tumors often preserve the ability to 
synthesize, store and secrete numerous hormones and biogenic amines which sometimes 
lead to distinct hypersecretory and clinically recognizable syndromes (such as carcinoid, 
Zollinger-Ellison, WDHA etc.).1 The resulting clinical symptoms are generally well 
controlled by somatostatin analogs and/or interferon-ǂ.2  
More often, GEP-NETs remain clinically silent until late, when they present with mass 
effect, and have unfortunately already locally or distantly spread. In the later case tumor 
growth and spread are not always well controlled by either biotherapy or chemotherapy. 
Although many biochemical and tissue markers for GEP-NETs already exist, sensitive and 
specific markers that predict tumor growth and behavior are lacking.3  
According to our unpublished data chromogranin A (CgA) and 5-hydroxyindolacetic acid 
(5-HIAA), currently used as standard biochemical markers of neuroendocrine tumors were 
only positive in 76.84% and 20.79% of GEP-NET cases respectively. Tumor markers were 
analyzed in 101 patients (61.2% with localized and 38.8% with metastatic disease) diagnosed 
with GEP-NETs. According to same investigation, CgA levels were much higher when 
tumors were part of MEN1 syndrome, while 5-HIAA levels were higher in case of metastatic 
disease, especially when hepatic metastases were present. When 5-HIAA values were 
compared among patients with different tumor localizations, the highest values were 
detected in patients with functional midgut tumors. This is consistent with data of other 
authors on biochemical diagnostics of gastrointestinal neuroendocrine tumors.4  
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Unfortunately, the correct diagnose of GEP-NETs is delayed for 7-10 years, additionally 
adding burden to anyhow complex and challenging tumor management.3 So, in clinical 
practice, more reliable serum markers as well as precise tumor localization of small, initial 
lesions together with incorporation of a histological grading system with implemented 
prognostic implications would help in optimal treatment of patients. The mentioned needs 
to be supported by better understanding of tumor cell biology and mechanistic regulation of 
underlying growth processes.5 
In general, majority of GEP-NETs are represented by well-differentiated cells, and one 
would expect low proliferating rate, but unfortunately, tumors often present metastatic at 
the time of diagnosis. This is one of the most intriguing characteristics, and has triggered 
scientific research aiming to demonstrate specific molecular features that could explain 
mechanisms underneath the ability of tumor cells to detach from primary malignancy and 
gain excess to the surrounding structures.6 
Although development of GEP-NETs is still unclear, significant breakthrough has been 
made in elucidating molecular genetics of neuroendocrine tumors exhibiting a hereditary 
background. Those rare tumor types (5-10% of all GEP-NETs) are often caused by mutations 
in tumor suppressor genes MEN1, VHL, NF-1, TSC1, and TSC2 which in turn lead to 
development of NETs as a part of multiple endocrine neoplasia type 1, von Hippel Lindau 
disease, neurofibromatosis type 1 and tuberous sclerosis complex respectively.7 Besides 
tumor suppression genes, studies have also demonstrated involvement of oncogenes, each 
of which may be associated with several different abnormalities that include point 
mutations, gene deletions, DNA methylation, chromosomal losses and chromosomal gains 
(Figure 1).3,8,9  
Perhaps the best characterized is the genetic background of the MEN1 syndrome, which in 
addition to neuroendocrine tumors of duodenum and pancreas includes adenomas/ 
hyperplasia of other endocrine glands (parathyroid hyperplasia/hyperparathyroidism, 
pituitary adenomas and adrenal cortical adenomas). It involves mutations of the MEN-1 
tumor suppressor gene. This chromosome 11q13 gene encodes protein menin  
which interacts with a number of proteins involved in the transcriptional regulation and 
genome stability, so it has been proposed to be a key player in regulating NET cell 
proliferation.8  
The MEN-1 gene, although conferring a high disease risk in MEN-1 patients where it 
represents a putative tumor suppressor gene accounts for less than 40 percent of sporadic 
GEP-NET cases.10 Thus, the genes involved in neuroendocrine tumorigenesis and the 
cellular roles of their proteins on proliferation and/or apoptotic pathways remain largely 
unknown. Studies of comparative genomic hybridization and allelic loss analysis have 
detected a large number of genomic regions with loss or gain of genetic material, further 
elucidating genetic differences between GEP-NETs of various primary localizations, and 
proving the heterogeneity of the tumors.11 
In general, foregut GEP-NETs often show loss of 11q, while tumors of midgut origin 
frequently show losses on chromosome 18q. The genetic abnormalities in hindgut NETs 
have not been well characterized, but it was noticed that larger tumors tend to express 
transforming growth factor-alpha (TGF-ǂ) more frequently, while epidermal growth factor 
receptor (EGFR) was expressed in all lesions.12  
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Fig. 1. Development of GEP-NETs. 
Comparative studies of pancreatic adenocarcinoma and pancreatic neuroendocrine tumors 
(pNETs) have helped in giving insight into cellular biology of those specific tumors. Unlike 
pancreatic adenocarcinomas, pNETs do not exhibit mutations in K-Ras oncogene or p53 
tumor suppressor gene, which are often mutated in the former. Also, the pattern of genomic 
alterations of pNETs differs from that of gastrointestinal NETs, where losses on 
chromosome 18q are almost a rule (occur in 38-88% of tumors).13  
It seems that specifics of pNET development are gains and losses of chromosomes, which 
also appear to influence disease stage. Specifically, genomic gains are common on 
chromosomes 4pq, 5pq, 7pq, 9q, 12q, 14q, 17pq, 18q and 20q, while losses occur on 
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chromosomes 1p, 3p, 6q, 10p, 11pq, X and Yq. It is interesting that nonfunctioning pNETs 
harbor more genetic changes than those functional; in particular they exhibit more losses of 
3p and mutations in MEN1 gene. The locus 3p is especially interesting while it harbors 
several tumor suppressor genes like VHL and retinoic receptor-beta (RAR-ǃ). The later, 
involved in induction of apoptosis, has been found hypermethylated in 25% of pNETS.14  
In addition to tumor suppressor genes, some oncogenes have also been found altered in 
pNETs. Those specifically include over expression of growth factor-related genes such as 
insulin like growth factor binding protein 3 (IGFBP3), cell adhesion and migration 
molecules as well as endothelial elements, suggesting an important role of tumor 
microenvironment.15 
Dysregulation of DNA methylation patterns is a central feature of colon carcinogenesis, and 
was also found to be present in development of gastrointestinal neuroendocrine tumors 
(especially carcinoids). This finding is interesting from the nutrigenomic point of view, and 
it raises the possibility of tumor prevention with folate and vitamin B12 
supplementation.16,17 
Positive immunohistochemistry staining for different cytokines and growth factors in the 
GEP-NETs as well as occurrence of GEP-NETs in the setting of inflammatory bowel disease 
led to the belief that chronic inflammation may play a crucial role in their development and 
that a number of more prevalent, low penetrance genes contribute to GEP-NET 
susceptibility in a larger population of patients.18  
With respect to the role of inflammatory signals in promoting the development of cancer, 
there is now emerging evidence for an important relationship between macrophage 
migration inhibitory (MIF) factor expression, oncogenesis and tumor progression. It seems 
that in different tumors MIF directly promotes tumorigenesis by inhibiting p53 
accumulation, promotes cellular proliferation through activation of members of the MAPK 
family and through induction of COX-2/PGE-2 influences tumor growth and viability. MIF 
was found to be co-secreted with adrenocorticotrophic hormone (ACTH) by the anterior 
pituitary, and it has the ability to override its antiinflammatory effects, thus promoting the 
inflammation and favouring protumor microinvironment.19 
It seems that immune system through the network of different cytokines and growth factors 
may also play permissive role in GEP-NET development (Figure 2).20  
It is now widely acknowledged that chronic inflammatory conditions can both pave the way 
for and sustain conditions favorable for carcinogenesis and tumor progression. Although 
the molecular mechanisms of this causal relationship remain to be elucidated, there is strong 
evidence of association between chronic inflammation and aproximately 1/5 of human 
cancers confirmed by numerous epidemiologic, gene association and molecular studies.21 
Overall, it appears that chronic inflammation more often stimulates then inhibits tumor 
development. The persistence of chronic inflammation plays a critical role in initiating, 
sustaining and advancing tumor growth, and thus modulating the immune response may 
still be an alluring goal for therapeutic intervention.22,23 
Although a pathogenic role for chronic inflammation has been suggested in multiple tumor 
systems in tumor initiation, progression and metastatic potential, the mechanism of this 
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important association is still not understood completely. The development of a tumor is 
associated with the growth and expansion of not only tumor cells but also stroma, vessels 
and infiltrating inflammatory cells, and it is the interaction between these different cell types 
that propagates tumor growth. Cytokines found in tumors, acting on paracrine and 
autocrine loops, are most likely the key players in the mentioned communication24, and for 
some of them link has been found between the serum and/or tumor tissue level and cancer 
survival.25 
 
Fig. 2. Connection between the endocrine system and cytokines. 
Cytokines and growth factors seem to largely contribute to the development and 
progression of GEP-NETs13,17,26,27, but their involvement in the autocrine stimulation of 
tumor cells, either in genesis and/or in the progression of GEP-NETs has not yet been 
clearly elucidated.28 
GEP-NETs represent a tumor entity with an extraordinary high vascularization along with 
an abundant production and secretion of growth factors, especially vascular endothelial 
growth factor (VEGF), epidermal growth factor (EGF), platelet-derived growth factor 
(PDGF), insulin like growth factor (IGF), fibroblast growth factor (FGF) and transforming 
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growth factor-ǂ (TGF-ǂ), which according to both observational and mechanistic data 
connect chronic inflammation with gastrointestinal carcinogenesis.20,23  
MEN-1 patients have a higher serum level of fibroblast growth factor (FGF), which 
correlates with the amount of tumor-associated fibroblastic response. Furthermore, insulin-
like growth factor-I (IGF-I) receptors found on GEP-NET cells suggest an autocrine trophic 
function for the mentioned growth factor in these tumors.27 Patients with carcinoid 
syndrome were found to have positive immunohistochemistry for TGF -ǃ on the right sided 
heart valves, as a consequence of NET progression and metastasis.29  
For further cancer evolution angiogenesis plays an important role. Proinflammatory 
cytokines such as tumor necrosis factor-ǂ (TNF-ǂ), IL1 and IL6 once again participate in 
this process by inducing the production of angiogenic factors, mainly VEGF. The role of 
vascular endothelial growth factor (VEGF) in the new vessel formation of these highly 
vascularized tumors is increasingly studied, and it appears to be involved in the 
metastasing process of the mentioned tumors. Higher levels of cytokines and growth 
factors detected in GEP-NETs are responsible for neurotrophic effects, smooth muscle cell 
hypertrophy and proliferation of both intimal and adventitial elastic tissue of the 
mesenteric blood vessels leading to vascular elastosis sometimes associated with ischemic 
changes of the near-by tissue (Figure 3).6,30  
 
 
 
 
 
 
 
 
Fig. 3. Tumor cell markers of neuroendocrine cell. 
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Cytokine genes are highly polymorphic, with polymorphisms frequently located in regions 
of DNA that regulate transcription, or posttranscriptional events, thus influencing 
functional activity. Recently published studies connected proinflammatory cytokine genes 
SNPs with cancer susceptibility and severity, putting them in the spot light as cancer-
modifier genes.31 This is particularly true for cytokine gene polymorphisms and 
gastrointestinal malignancy, where many authors suggest the role of inflammation-
mediated oncogenesis.16,18,32 It seems likely that they also contribute to GEP-NET 
development.33,34 
Genetic polymorphisms directly influence interindividual variation in the cytokine 
response, and this clearly contributes to an individual’s ultimate clinical outcome. Many 
single nucleotide polymorphisms (SNPs) have been detected within the cytokine gene 
sequences, particularly within the promoter regions. Several of these SNPs may be 
associated with differential level of gene transcription, thus influencing levels of cytokines 
and growth factors in sera and tumor tissue and ultimately altering the disease prognosis by 
influencing anti-tumor immunologic response or pathways of (neo)angiogenesis.  
However, for the ultimate outcome, not only cytokines or growth factors but also (tumor) 
cell type and stimulus may also be important.35 In our investigation of the role of IL-6 in 
GEP-NETs we have found the significantly higher proportion of high expression genotypes 
(-174 C/G and G/G) in the nonfunctioning pNETs, discriminating them from functional 
pNETs and gastrointestinal NETs (mainly of midgut origin). Mentioned patients had also 
higher concentrations of IL-6 in their sera (it was overall elevated in 36.8% of patients), 
suggesting the potential role of IL-6 as a novel diagnostic and prognostic marker of 
nonfunctioning pNETs.36 
A number of studies have reported associations between TNF-ǂ promoter SNPs with high 
expression alleles (-238A, -308A, -1031C) and susceptibility to cancer.20,37 Our ongoing 
studies have strongly confirmed the role of TNF-ǂ -1031C (high expression) allele as a 
potential risk factor for developing GEP-NET. Also, we have found the higher level of the 
-308 high expression genotypes (AG, AA) as well as high expression -308A allele among 
the patients contracting foregut GEP-NETs than in those with midgut tumors. This 
finding may provide better insight in the role of cytokines in the development of different 
GEP-NET types and differentiation, and possibly open new prospective in GEP-NET 
treatment.38 
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